Dexcom vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Diego CGM diabetes technology (NASDAQ: DXCM) ~$3.9B 2024 revenue; G7 prescription CGM market leader, Stelo OTC CGM launched 2024, $75M Oura Ring investment/integration competing with Abbott FreeStyle Libre.
About
Dexcom, Inc. is a San Diego, California-based diabetes management technology company — publicly traded on NASDAQ (NASDAQ: DXCM) as an S&P 500 Health Care component — developing and commercializing continuous glucose monitoring (CGM) systems for people with Type 1 diabetes, Type 2 diabetes, and pre-diabetes through approximately 9,000 employees worldwide. Dexcom's G7 CGM system (a small wearable sensor and transmitter worn on the body that measures glucose continuously every 5 minutes without fingerstick calibration) is the market-leading prescription CGM for insulin-using patients — enabling tight glucose management that prevents hypoglycemic episodes, reduces A1c levels, and improves outcomes for the 8+ million US patients using insulin. In 2024, Dexcom launched Stelo — the first FDA-cleared over-the-counter CGM in the United States, requiring no prescription and targeting the approximately 25 million US adults with Type 2 diabetes who do not use insulin, pre-diabetes patients, and health-conscious consumers seeking metabolic insights. The Stelo OTC CGM integrates with the Oura Ring (wearable health tracking) through a strategic partnership announced in November 2024, with Dexcom investing $75 million in ŌURA and the companies launching Stelo integration in the Oura app — giving users 24/7 glucose insights alongside sleep, heart rate, and activity data from the Oura Ring. Dexcom reported full year 2024 revenue of approximately $3.9 billion, with continued CGM market penetration driving growth.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.